| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5508269 | MYLAN SPECIALITY LP | Aminoglycoside formulation for aerosolization |
Oct, 2014
(9 years ago) | |
Tobi is owned by Mylan Speciality Lp.
Tobi contains Tobramycin.
Tobi has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Tobi are:
- US5508269
Tobi was authorised for market use on 22 December, 1997.
Tobi is available in solution;inhalation dosage forms.
Tobi can be used as treatment of cystic fibrosis patients with pseudomonas aeruginosa.
The generics of Tobi are possible to be released after 19 October, 2014.
Drugs and Companies using TOBRAMYCIN ingredient
Market Authorisation Date: 22 December, 1997
Treatment: Treatment of cystic fibrosis patients with pseudomonas aeruginosa
Dosage: SOLUTION;INHALATION
How can I launch a generic of TOBI before it's drug patent expiration?
More Information on Dosage
TOBI family patents
